Here’s the problem with the drug industry’s top talking point: It’s a lie.
Through successive initiatives and in collaboration with a diverse group of committed stakeholders, PBGH has spearheaded efforts to create a blueprint for “advanced primary care.”
The COVID-19 global pandemic and resulting economic slowdown had profound impacts on many sectors, including tourism, aviation, oil, finance and health care.
With 60% of Americans getting their health care coverage through their jobs, large and small employers alike are justifiably concerned about rising costs of care.
Throughout the COVID-19 pandemic, employers have stepped up to lead, taking the actions necessary to protect their employees and their businesses. And the recent trend of vaccine mandates and incentives is just the latest example of that.
In 2017, pharmacy giant CVS announced it was purchasing insurer Aetna for $69 billion in the largest-ever health care merger.
The United States is facing a crisis when it comes to health care costs. Prices for lifesaving, necessary care and drugs are simply too high for consumers.
Ever-rising health care costs are causing many across the political spectrum to rethink their priorities and positions on key health care policy issues.
Operating largely beneath the public and regulatory radar, private equity firms have gravitated toward health care over the past decade in pursuit of outsized profits.
An eleventh-hour bid by private equity companies, hospitals and other provider interests threatens to torpedo Congress’ objectives of protecting patients from exorbitant, surprise medical bills and constraining soaring health care costs.